This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

This study has been completed.
Information provided by:
Celgene Identifier:
First received: August 16, 2002
Last updated: September 22, 2009
Last verified: September 2009
The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.

Condition Intervention Phase
Multiple Myeloma Drug: CDC-501 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study to Evaluate the Efficacy and Safety of Two CDC-501 Dose Regimens When Used Alone or in Combination With Dexamethasone for the Treatment Relapsed or Refractory Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by Celgene:

Enrollment: 102
Study Start Date: April 2002
Study Completion Date: December 2004
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Subject must be diagnosed with multiple myeloma (with measurable M-Protein in serum and/or urine), and be considered to have disease progression after at least two cycles of treatment or have relapsed after treatment.
  • Subject must understand and voluntarily sign an informed consent document.
  • Subject must not have received corticosteroids, other chemotherapy, thalidomide, or other investigational agents, within 21 days of baseline
  • ECOG (Zubrod) performance status of 0 to 2.
  • Subject must be able to adhere to the study visit schedule and other protocol requirements.
  • Women of childbearing potential (WCBP ) must have a negative serum or urine pregnancy test within 7 days of baseline. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00044018

United States, Florida
H Lee Moffit Cancer Center
Tampa, Florida, United States, 33612
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55902
United States, New York
St Vincent's Cancer Center
New York, New York, United States, 10011
Sponsors and Collaborators
Celgene Corporation
Study Director: Robert Knight, MD Celgene Corporation
  More Information

Responsible Party: Robert Knight MD - VP Hematology, Celgene Corporation Identifier: NCT00044018     History of Changes
Other Study ID Numbers: CC-5013-MM-007
Study First Received: August 16, 2002
Last Updated: September 22, 2009

Keywords provided by Celgene:

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents processed this record on September 18, 2017